Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

All Conditions

Behaviors and Mental Disorders

Neoplasms

Urinary Incontinence

Enuresis

Urinary Incontinence, Stress

Uterine Neoplasms

Endometrial Neoplasms

Nocturnal Enuresis

Urination Disorders

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Lower Urinary Tract Symptoms

Urological Manifestations

Behavioral Symptoms

Elimination Disorders

Mental Disorders

Psychotic Disorders

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Concurrent treatment of endometrial cancer and SUI may improve QOL, emotional and physical health and decrease costs for both patients and the health care system. At the time of endometrial cancer diagnosis, not only are women evaluated by a gynecologist and/or a gynecologic oncologist, but the majority will undergo surgery within weeks of their diagnosis. Thus, urinary incontinence could easily be identified, a referral made, and concurrent surgery performed. This would spare the patient two surgeries, decrease the emotional distress associated with SUI symptoms, decrease the costs associated with SUI for the patient and possibly improve overall quality of life. The proposed study will compare the quality of life and clinical outcomes among women with endometrial cancer and SUI that have concurrent surgery to women that do not have concurrent surgery. The findings of our proposed research will provide valuable information necessary for woman and clinicians to make decisions regarding the treatment of SUI, including evidence regarding the risks and benefits of performing concurrent endometrial cancer and SUI surgery.

Cancer of the Uterus and Treatment of Stress Urinary Incontinence

The purpose of this study is to compare quality of life among women with endometrial cancer and SUI who undergo SUI and endometrial cancer surgery simultaneously to women that do not.

Compare the sexual function of women with endometrial cancer and SUI who have concurrent surgery to women who have cancer surgery only. Sexual function will be measured using the female sexual function index (FSFI). It is a 19-item instrument assessing 6 domains of sexual function: desire, arousal, lubrication, orgasm, satisfaction, and pain.

Compare the clinical outcomes of women with endometrial cancer and SUI who have concurrent surgery to women who have cancer surgery only, by measuring time to surgery (ie: number of days) using hospital records. The estimated time to surgery will be assessed up to 12 weeks, measuring from initial date of enrollment to date of documented surgery date.

Compare the clinical outcomes of women with endometrial cancer and SUI who have concurrent surgery to women who have cancer surgery only by examining surgical outcomes such as intra op injuries or complications using hospital records.

Compare the clinical outcomes of women with endometrial cancer and SUI who have concurrent surgery to women who have cancer surgery only by examining Post-Operative complications. We will document any treatment-related adverse events as assessed by CTCAE v4.0. We will use hospital records.

Compare the rate of midurethral sling complications among women who received radiation after sling placement to women who did not receive radiation using hospital records.

We will also measure post-operative pain, using the modified Brief Pain Inventory (BPI) scale.

University of Alabama at Birmingham

Hartford Hospital

Women and Infants Hospital of Rhode Island

Prostatic Neoplasms

Prostatic Hyperplasia

Hyperplasia

Urinary Incontinence, Urge

Genital Neoplasms, Male

Genital Diseases, Male

Prostatic Diseases

The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.

Elidah Device

Theresa Cooley Zgela, R.N.

Deborah E Citrin, M.D.

National Cancer Institute Referral Office

Background:

Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.

Objective:

To see if the Elidah device can reduce urinary incontinence after prostate treatment.

Eligibility:

Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.

Design:

Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.

The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.

Participants will be given an Elidah device and taught how to use it at home.

They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.

Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.

Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.

Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.

Participants will complete 15-minute questionnaires.

Background:

* Urinary incontinence is a common side effect of prostate cancer therapy that can negatively impact the quality of life.
* Standard treatment includes an initial course of pelvic floor muscle exercises followed by surgical therapy if urinary incontinence persists.
* Although pelvic floor muscle exercises can be successful in reducing urinary incontinence, compliance with exercises is poor.
* The Elitone (registered trademark) device was recently cleared by the Food and Drug Administration (FDA) for use in women with stress urinary incontinence. This device provides a surface electrical muscle stimulation device designed to contract the pelvic floor muscles and has been shown to reduce incontinence in women using the product.
* Recently, the electrode component (GelPad) of the device has been adapted for use in men by the manufacturing company, Elidah. The male version of the device is named the Elidah device.

Objective:

-To describe the efficacy of the Elidah device on male urinary incontinence

Eligibility:

* Participants must be male.
* Participants must have a history of urinary incontinence for at least 6 months after prostate cancer treatment.
* Participants must have at least one of the following types of urinary incontinence:

  * stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities), or on sneezing or coughing;
  * urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.

Design:

* This is a phase II trial testing the efficacy of the Elidah device in people treated for prostate cancer with stress and/or urge urinary incontinence.
* Prior to treatment, participants will undergo baseline assessments including 24-hour pad weight testing and questionnaires relating to incontinence and quality of life.
* Participants will self-administer the Elidah device treatment for 20 minutes per day, 5 days per week during a 6-week period in the at-home environment. Participants will maintain a Daily Log to record usage of the Elidah device, urinary leaks, and use of pads during each week of treatment.
* Following 6 weeks of therapy, participants will undergo re-evaluation of symptoms and urinary incontinence via questionnaires and testing with the 24-hour pad weight test.

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

.All IPD recorded in the medical record will be shared with intramural investigators upon request.

Percent decrease in 24-hour pad weight after treatment with the Elidah device.

Frequency of adverse events among treated participants and reporting the results, by maximum grade of event and type of toxicity noted.

Evaluated by the number of pads and number of leaks before and after treatment. The mean of the percent reduction in the number of pads used per day following treatment will be computed along with 95% confidence intervals.

The proportion of participants for which the I-QoL score improves by 2.5 points or more following six weeks of Elidah device use will be estimated. 95% confidence intervals for this proportion will be constructed.

A test of binomial proportions will be performed to assess whether the treatment noncompliance rate is above the unacceptability threshold.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cancer of the Uterus and Treatment of Stress Urinary Incontinence	NCT02667431	Endometrial Can... Stress Urinary ...		18 Years - 100 Years	Women and Infants Hospital of Rhode Island
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer	NCT06161506	Urinary Urge In... Stress Urinary ... Prostatic Hyper...	Elidah Device	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer	NCT06161506	Urinary Urge In... Stress Urinary ... Prostatic Hyper...	Elidah Device	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for stress urinary incontinence